EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Bispecific antibody combination therapies in diffuse large B‐cell lymphoma

Sean Harrop iD, Adrian Minson, Thiago M Steiner, Paul J Neeson iD, Michael J Dickinson iD

British Journal of Haematology · 2026

DOI: 10.1111/bjh.70228 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Sean Harrop und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Antibodies, Bispecific, Antineoplastic Combined Chemotherapy Protocols, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 111 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bispecific T‐cell‐engaging antibodies (TCEs) are a significant advance in the treatment of diffuse large B‐cell lymphoma (DLBCL), demonstrating robust clinical activity with manageable toxicity profiles. Their integration into third line as monotherapy, and now second line in combination, as well as recent data in the first line underscores their therapeutic potential. The efficacy of bispecific antibodies depends on sustained target antigen expression and preserved T‐cell function; the loss of either of these factors, or intrinsic tumour and microenvironment biology, contributes to therapeutic resistance. Combination strategies aim to overcome these resistance mechanisms, enhance anti‐tumour efficacy and potentially reduce treatment‐related adverse events. In this review, we critically examine the current understanding of TCE resistance and discuss how this informs combination strategies. We explore approaches to bispecific antibody‐based combination therapies in DLBCL and review emerging clinical trial results, with a view on potential future strategies for TCE‐based combinations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseAntibodies, BispecificAntineoplastic Combined Chemotherapy ProtocolsAntineoplastic Agents, ImmunologicalHumansTumor Microenvironment

Stichwörter der Autor:innen

DLBCLbispecificcombination

Substanzen

Antibodies, BispecificAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Clinical Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
  • Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

ORCID-Profile: Sean Harrop, Paul J Neeson, Michael J Dickinson

Zitieren

APA

Harrop, S., Minson, A., Steiner, T. M., Neeson, P. J., & Dickinson, M. J. (2026). Bispecific antibody combination therapies in diffuse large B‐cell lymphoma. British Journal of Haematology. https://doi.org/10.1111/bjh.70228

Vancouver

Harrop S, Minson A, Steiner TM, Neeson PJ, Dickinson MJ. Bispecific antibody combination therapies in diffuse large B‐cell lymphoma. British Journal of Haematology. 2026. doi:10.1111/bjh.70228

BibTeX
@article{Harrop2026,
  author = {Harrop, Sean and Minson, Adrian and Steiner, Thiago M and Neeson, Paul J and Dickinson, Michael J},
  title = {Bispecific antibody combination therapies in diffuse large B‐cell lymphoma},
  journal = {British Journal of Haematology},
  year = {2026},
  doi = {10.1111/bjh.70228}
}
Kostenlos starten →